PEComa Market Emerging as a High-Growth Healthcare Investment Space Through 2036 - DelveInsight | Aadi Bioscience, Sarcoma Oncology, Novartis

The Key PEComa Companies in the market include - Aadi Bioscience, Sarcoma Oncology, Novartis, and others.

DelveInsight's report, "PEComa Market Insights, Epidemiology, and Market Forecast-2036" provides a comprehensive analysis of the PEComa landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines PEComa market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

Get a Free sample for the PEComa Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/pecoma-market [https://www.delveinsight.com/report-store/pecoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the PEComa Market Report:

*
The PEComa market size was valued at nearly USD 45 million in 2025 and is anticipated to reach approximately USD 135 million by 2036, expanding at a CAGR of 8.1% during the 2026-2036 forecast period.

*
In March 2025, Aadi Bioscience has been reorganized into two entities. Following the divestiture of Aadi Sub to KAKEN, KAKEN assumes ownership of Aadi Sub, including the Aadi name, trademark, and the FYARRO Registered business. The remaining parent company has been renamed Whitehawk Therapeutics, focusing on its portfolio of ADC assets.

*
In December 2024, Aadi Bioscience entered an agreement to sell its commercial drug FYARRO to KAKEN Pharmaceutical for USD 100 million, alongside a USD 100 million PIPE equity financing and an exclusive license for a three-asset preclinical ADC portfolio in collaboration with WuXi Biologics and Hangzhou DAC. In March 2025, the company's stockholders approved the sale of FYARRO to KAKEN.

*
According to the estimates, the largest market size of PEComa was captured by the United States, i.e., ~USD 114 million by 2036.

*
The PEComa treatment landscape is evolving as management shifts from conventional approaches toward more molecularly targeted strategies, with mTOR inhibitors such as Sirolimus and Everolimus driving adoption due to their demonstrated efficacy in TSC1/TSC2-altered tumors, while emerging use of immunotherapies like Keytruda and other precision approaches is gaining interest in advanced or refractory cases.

*
Regional market dynamics for PEComa show the United States leading in revenue, while markets in Japan and European Union demonstrate steady growth, reflecting improved diagnostic awareness, greater access to targeted therapies and increasing adoption of emerging treatment approaches in rare tumor management.

*
In 2036, among all the therapies for PEComa, the highest revenue is estimated to be generated by FYARRO, in the United States.

*
According to DelveInsight's estimates, the total prevalent cases of PEComa in the 7MM were approximately 408 in 2025.

*
Among EU4 and the UK, Germany accounts for the highest incidence of PEComas, followed by France and the UK.

*
In 2025, Perivascular Epithelioid Cell Neoplasm (PEComa) by stage in the US, benign tumor is the most prevalent subtype with ~67% followed by local aggressive behavior (malignant PEComa) accounting for ~33%.

*
The observed female predominance and earlier onset of PEComa highlight the importance of gender-specific screening and early intervention strategies, particularly in recognizing susceptibility patterns and addressing disease at onset to prevent long-term complications.

*
Aadi Bioscience's FYARRO is the only approved therapy for PEComa.

*
Key PEComa Companies: Aadi Bioscience, Sarcoma Oncology, Novartis, and others

*
Key PEComa Therapies: FYARRO (sirolimus protein-bound), Nab-Rapamycin, Everolimus, and others

*
The PEComa market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage PEComa pipeline products will significantly revolutionize the PEComa market dynamics.

PEComa Overview

PEComa (Perivascular Epithelioid Cell Tumor) is a rare type of mesenchymal tumor that arises from perivascular epithelioid cells specialized cells typically located around blood vessels. These tumors can develop in various parts of the body, including the kidneys, liver, lungs, uterus, gastrointestinal tract, and soft tissues. PEComas belong to a broader group of tumors known as PEComatous tumors, which also includes angiomyolipoma and lymphangioleiomyomatosis.

PEComa is considered a rare cancer, and its exact cause is not fully understood. However, some cases are associated with genetic mutations linked to tuberous sclerosis complex (TSC), which affects the mTOR signaling pathway involved in cell growth and proliferation. Because of this pathway involvement, mTOR inhibitors have become an important targeted treatment option.

To Know in detail about the PEComa market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; PEComa Market Forecast [https://www.delveinsight.com/sample-request/pecoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

PEComa Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

PEComa Epidemiology Segmentation:

The PEComa market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

*
Total Prevalence of PEComa

*
Prevalent Cases of PEComa by severity

*
Gender-specific Prevalence of PEComa

*
Diagnosed Cases of Episodic and Chronic PEComa

Download the report to understand which factors are driving PEComa epidemiology trends @ PEComa Epidemiology Forecast [https://www.delveinsight.com/sample-request/pecoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

PEComa Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the PEComa market or expected to get launched during the study period. The analysis covers PEComa market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the PEComa Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

PEComa Therapies and Key Companies

*
Sirolimus protein-bound/ABI-009 (FYARRO): Kaken Pharmaceuticals

*
Pembrolizumab (KEYTRUDA): Merck Sharp & Dohme

*
FYARRO (sirolimus protein-bound): Aadi Bioscience

*
Nab-Rapamycin: Sarcoma Oncology

*
Everolimus: Novartis

Discover more about therapies set to grab major PEComa market share @ PEComa Treatment Landscape [https://www.delveinsight.com/sample-request/pecoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

PEComa Market Drivers

*
Increasing awareness of rare cancers, leading to improved diagnosis and reporting of PEComa cases.

*
Advancements in targeted therapies, particularly the development and use of mTOR inhibitors for PEComa treatment.

*
Growing investment in rare disease research and drug development by pharmaceutical and biotechnology companies.

*
Regulatory incentives for orphan drugs, encouraging companies to develop therapies for rare tumors like PEComa.

*
Rising number of clinical trials exploring novel targeted therapies and immunotherapies.

PEComa Market Barriers

*
Extremely small patient population, which limits large-scale clinical trials and commercial opportunities.

*
Limited approved treatment options, resulting in reliance on off-label therapies or experimental treatments.

*
High cost of targeted therapies, which can restrict patient access in some regions.

*
Challenges in early diagnosis, as PEComa symptoms are often nonspecific and the disease is rare.

*
Lack of standardized treatment guidelines due to limited clinical data and case studies.

Scope of the PEComa Market Report

*
Study Period: 2022-2036

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key PEComa Companies: Aadi Bioscience, Sarcoma Oncology, Novartis, and others

*
Key PEComa Therapies: FYARRO (sirolimus protein-bound), Nab-Rapamycin, Everolimus, and others

*
PEComa Therapeutic Assessment: PEComa current marketed and PEComa emerging therapies

*
PEComa Market Dynamics: PEComa market drivers and PEComa market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
PEComa Unmet Needs, KOL's views, Analyst's views, PEComa Market Access and Reimbursement

To know more about PEComa companies working in the treatment market, visit @ PEComa Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/pecoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. PEComa Market Report Introduction

2. Executive Summary for PEComa

3. SWOT analysis of PEComa

4. PEComa Patient Share (%) Overview at a Glance

5. PEComa Market Overview at a Glance

6. PEComa Disease Background and Overview

7. PEComa Epidemiology and Patient Population

8. Country-Specific Patient Population of PEComa

9. PEComa Current Treatment and Medical Practices

10. PEComa Unmet Needs

11. PEComa Emerging Therapies

12. PEComa Market Outlook

13. Country-Wise PEComa Market Analysis (2022-2036)

14. PEComa Market Access and Reimbursement of Therapies

15. PEComa Market Drivers

16. PEComa Market Barriers

17. PEComa Appendix

18. PEComa Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=pecoma-market-emerging-as-a-highgrowth-healthcare-investment-space-through-2036-delveinsight-aadi-bioscience-sarcoma-oncology-novartis]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.